Syndax Pharmaceuticals IncNASDAQ:SNDX
- LAST PRICE18.2700
- TODAY'S CHANGE (%)-0.3600 (-1.9324%)
- Bid / Lots18.1800/ 4
- Ask / Lots18.2400/ 1
- Open / Previous Close18.6400 / 18.6300
- Day Range
- 52 Week Range
- Volume1,233,888
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNDX |
|---|---|---|
| 09:32 ET | 140972 | 18.61 |
| 09:36 ET | 100 | 18.55 |
| 09:39 ET | 200 | 18.6 |
| 09:41 ET | 100 | 18.61 |
| 09:45 ET | 200 | 18.525 |
| 09:48 ET | 700 | 18.6 |
| 09:50 ET | 2137 | 18.48 |
| 09:54 ET | 2909 | 18.52 |
| 10:01 ET | 536 | 18.61 |
| 10:03 ET | 900 | 18.64 |
| 10:06 ET | 3947 | 18.6 |
| 10:08 ET | 200 | 18.595 |
| 10:10 ET | 400 | 18.56 |
| 10:12 ET | 400 | 18.47 |
| 10:14 ET | 952 | 18.48 |
| 10:15 ET | 779 | 18.47 |
| 10:17 ET | 293 | 18.52 |
| 10:19 ET | 3379 | 18.5494 |
| 10:21 ET | 900 | 18.55 |
| 10:28 ET | 200 | 18.575 |
| 10:30 ET | 300 | 18.55 |
| 10:32 ET | 1017 | 18.56 |
| 10:33 ET | 200 | 18.53 |
| 10:35 ET | 1642 | 18.54 |
| 10:37 ET | 400 | 18.585 |
| 10:42 ET | 200 | 18.59 |
| 10:44 ET | 400 | 18.6 |
| 10:48 ET | 1306 | 18.57 |
| 10:51 ET | 100 | 18.575 |
| 10:53 ET | 1900 | 18.57 |
| 10:55 ET | 6000 | 18.595 |
| 10:57 ET | 3400 | 18.615 |
| 11:00 ET | 500 | 18.63 |
| 11:02 ET | 3800 | 18.6 |
| 11:04 ET | 2900 | 18.59 |
| 11:06 ET | 4700 | 18.61 |
| 11:08 ET | 6368 | 18.605 |
| 11:09 ET | 601 | 18.605 |
| 11:11 ET | 4024 | 18.585 |
| 11:13 ET | 9307 | 18.62 |
| 11:15 ET | 5288 | 18.68 |
| 11:18 ET | 1053 | 18.65 |
| 11:20 ET | 237 | 18.66 |
| 11:22 ET | 266 | 18.68 |
| 11:24 ET | 22014 | 18.54 |
| 11:26 ET | 1123 | 18.535 |
| 11:27 ET | 548 | 18.55 |
| 11:29 ET | 520 | 18.53 |
| 11:31 ET | 421 | 18.45 |
| 11:33 ET | 2015 | 18.42 |
| 11:36 ET | 300 | 18.445 |
| 11:38 ET | 1121 | 18.5 |
| 11:40 ET | 3612 | 18.52 |
| 11:44 ET | 493 | 18.5 |
| 11:45 ET | 700 | 18.5 |
| 11:47 ET | 3952 | 18.5 |
| 11:49 ET | 2484 | 18.52 |
| 11:51 ET | 3004 | 18.54 |
| 11:54 ET | 1500 | 18.5 |
| 11:58 ET | 50200 | 18.505 |
| 12:00 ET | 500 | 18.51 |
| 12:02 ET | 1352 | 18.42 |
| 12:03 ET | 1000 | 18.435 |
| 12:05 ET | 423 | 18.44 |
| 12:07 ET | 2140 | 18.42 |
| 12:09 ET | 1473 | 18.48 |
| 12:12 ET | 100 | 18.49 |
| 12:14 ET | 2769 | 18.5 |
| 12:16 ET | 526 | 18.52 |
| 12:18 ET | 100 | 18.505 |
| 12:20 ET | 1641 | 18.49 |
| 12:21 ET | 200 | 18.47 |
| 12:23 ET | 1496 | 18.48 |
| 12:27 ET | 309 | 18.48 |
| 12:30 ET | 9334 | 18.45 |
| 12:32 ET | 1070 | 18.445 |
| 12:34 ET | 100 | 18.46 |
| 12:36 ET | 300 | 18.45 |
| 12:38 ET | 8186 | 18.42 |
| 12:39 ET | 1600 | 18.425 |
| 12:41 ET | 600 | 18.42 |
| 12:43 ET | 600 | 18.42 |
| 12:48 ET | 4363 | 18.42 |
| 12:50 ET | 3718 | 18.46 |
| 12:54 ET | 200 | 18.47 |
| 12:56 ET | 100 | 18.51 |
| 12:57 ET | 1000 | 18.48 |
| 12:59 ET | 1706 | 18.49 |
| 01:01 ET | 961 | 18.48 |
| 01:03 ET | 900 | 18.46 |
| 01:08 ET | 100 | 18.47 |
| 01:10 ET | 1279 | 18.47 |
| 01:12 ET | 600 | 18.51 |
| 01:14 ET | 300 | 18.52 |
| 01:15 ET | 200 | 18.48 |
| 01:17 ET | 100 | 18.49 |
| 01:19 ET | 1645 | 18.49 |
| 01:21 ET | 200 | 18.48 |
| 01:24 ET | 1350 | 18.46 |
| 01:26 ET | 200 | 18.45 |
| 01:28 ET | 400 | 18.46 |
| 01:30 ET | 300 | 18.43 |
| 01:32 ET | 1042 | 18.46 |
| 01:33 ET | 200 | 18.5 |
| 01:35 ET | 1100 | 18.48 |
| 01:37 ET | 100 | 18.47 |
| 01:39 ET | 1125 | 18.45 |
| 01:42 ET | 1235 | 18.49 |
| 01:44 ET | 1213 | 18.47 |
| 01:46 ET | 800 | 18.475 |
| 01:48 ET | 700 | 18.445 |
| 01:50 ET | 100 | 18.43 |
| 01:51 ET | 400 | 18.46 |
| 01:53 ET | 700 | 18.435 |
| 01:55 ET | 200 | 18.42 |
| 01:57 ET | 300 | 18.42 |
| 02:00 ET | 6407 | 18.45 |
| 02:02 ET | 693 | 18.45 |
| 02:04 ET | 1023 | 18.44 |
| 02:06 ET | 3000 | 18.43 |
| 02:09 ET | 200 | 18.42 |
| 02:11 ET | 789 | 18.42 |
| 02:13 ET | 9972 | 18.43 |
| 02:15 ET | 500 | 18.455 |
| 02:18 ET | 100 | 18.44 |
| 02:20 ET | 700 | 18.44 |
| 02:22 ET | 800 | 18.45 |
| 02:24 ET | 100 | 18.44 |
| 02:26 ET | 600 | 18.43 |
| 02:27 ET | 621 | 18.465 |
| 02:29 ET | 215 | 18.46 |
| 02:31 ET | 1106 | 18.45 |
| 02:33 ET | 300 | 18.455 |
| 02:36 ET | 200 | 18.44 |
| 02:38 ET | 300 | 18.44 |
| 02:40 ET | 977 | 18.48 |
| 02:42 ET | 300 | 18.47 |
| 02:44 ET | 200 | 18.47 |
| 02:45 ET | 300 | 18.5 |
| 02:47 ET | 1619 | 18.53 |
| 02:49 ET | 1027 | 18.55 |
| 02:51 ET | 200 | 18.56 |
| 02:54 ET | 1803 | 18.57 |
| 02:56 ET | 700 | 18.58 |
| 02:58 ET | 2407 | 18.56 |
| 03:00 ET | 1032 | 18.55 |
| 03:02 ET | 2108 | 18.54 |
| 03:03 ET | 1250 | 18.57 |
| 03:05 ET | 488 | 18.56 |
| 03:07 ET | 1385 | 18.55 |
| 03:09 ET | 1516 | 18.52 |
| 03:12 ET | 300 | 18.52 |
| 03:14 ET | 714 | 18.52 |
| 03:16 ET | 600 | 18.53 |
| 03:18 ET | 3338 | 18.49 |
| 03:20 ET | 223 | 18.53 |
| 03:21 ET | 600 | 18.53 |
| 03:23 ET | 300 | 18.52 |
| 03:25 ET | 1200 | 18.515 |
| 03:27 ET | 430 | 18.53 |
| 03:30 ET | 800 | 18.53 |
| 03:32 ET | 200 | 18.535 |
| 03:34 ET | 1609 | 18.51 |
| 03:36 ET | 1349 | 18.5 |
| 03:38 ET | 2194 | 18.52 |
| 03:39 ET | 1007 | 18.56 |
| 03:41 ET | 4681 | 18.56 |
| 03:43 ET | 1331 | 18.55 |
| 03:45 ET | 2074 | 18.56 |
| 03:48 ET | 3934 | 18.55 |
| 03:50 ET | 2881 | 18.555 |
| 03:52 ET | 6234 | 18.51 |
| 03:54 ET | 4098 | 18.48 |
| 03:56 ET | 19704 | 18.41 |
| 03:57 ET | 11461 | 18.35 |
| 03:59 ET | 470969 | 18.27 |
Sep 18, 2024
Sep 6, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 4:05PM ET on Friday Sep 06, 2024 by Dow Jones
4:05PM ET on Friday Sep 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Syndax Pharmaceuticals Inc | 1.6B | -5.4x | --- |
Kura Oncology Inc | 1.6B | -9.4x | --- |
Spyre Therapeutics Inc | 1.5B | -2.0x | --- |
Belite Bio Inc | 1.5B | -39.5x | --- |
Cassava Sciences Inc | 1.5B | -73.5x | --- |
Viridian Therapeutics Inc | 1.7B | -5.3x | --- |
Company Information
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Contact Information
- Headquarters
- 35 Gatehouse Drive, Building D, Floor 3WALTHAM, MA, United States 02451
- Phone
- 781-419-1400
- Fax
- 781-419-1420
Executives
- Independent Chairman of the Board
- Dennis Podlesak
- President, Head of Research and Development
- Neil Gallagher
- Chief Executive Officer, Director
- Michael Metzger
- Chief Financial Officer
- Keith Goldan
- General Counsel, Secretary
- Luke Albrecht
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $3.5M |
Shares Outstanding | 85.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $-3.38 |
Book Value | $6.53 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 453.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,228.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
